"Therapeutic Equivalency" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease.
| Descriptor ID |
D013810
|
| MeSH Number(s) |
G03.787.559 G07.690.725.898
|
| Concept/Terms |
Therapeutic Equivalency- Therapeutic Equivalency
- Clinical Equivalencies
- Equivalencies, Clinical
- Equivalency, Clinical
- Generic Equivalency
- Equivalencies, Generic
- Equivalency, Generic
- Generic Equivalencies
- Equivalencies, Therapeutic
- Therapeutic Equivalencies
- Equivalency, Therapeutic
- Bioequivalence
- Bioequivalences
- Clinical Equivalency
|
Below are MeSH descriptors whose meaning is more general than "Therapeutic Equivalency".
Below are MeSH descriptors whose meaning is more specific than "Therapeutic Equivalency".
This graph shows the total number of publications written about "Therapeutic Equivalency" by people in this website by year, and whether "Therapeutic Equivalency" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 0 | 1 |
| 2009 | 1 | 2 | 3 |
| 2010 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Therapeutic Equivalency" by people in Profiles.
-
Zheng R, Lam E, Altshuler P, Crutcher M, Lavu H, Yeo CJ, Stickle D, Leiby B, Kraft WK. Pharmacokinetics of apixaban in patients undergoing pancreaticoduodenectomy (PAP-UP). Int J Clin Pharmacol Ther. 2024 Jul; 62(7):319-325.
-
Choudhry NK, Denberg TD, Qaseem A. Improving Adherence to Therapy and Clinical Outcomes While Containing Costs: Opportunities From the Greater Use of Generic Medications: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2016 Jan 05; 164(1):41-9.
-
Blackstone EA, Fuhr JP. Biosimilars and innovation: an analysis of the possibility of increased competition in biopharmaceuticals. Future Med Chem. 2010 Nov; 2(11):1641-9.
-
Colon-Gonzalez F, Kraft WK. Pharmacokinetic evaluation of fosaprepitant dimeglumine. Expert Opin Drug Metab Toxicol. 2010 Oct; 6(10):1277-86.
-
Fuhr JP. Biosimilars and follow-on biologics. Expert Rev Pharmacoecon Outcomes Res. 2009 Apr; 9(2):149-50.
-
Cushing DJ, Adams MP, Cooper WD, Kowey PR, Lipicky RJ. Bioequivalence of 2 intravenous amiodarone formulations in healthy participants. J Clin Pharmacol. 2009 Apr; 49(4):407-15.
-
Varki R, Pequignot E, Leavitt MC, Ferber A, Kraft WK. A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study. BMC Clin Pharmacol. 2009; 9:2.
-
Chervoneva I, Hyslop T, Hauck WW. A multivariate test for population bioequivalence. Stat Med. 2007 Mar 15; 26(6):1208-23.
-
Whitson JT, Ochsner KI, Moster MR, Sullivan EK, Andrew RM, Silver LH, Wells DT, James JE, Bosworth CF, Dickerson JE, Landry TA, Bergamini MV. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1. Ophthalmology. 2006 Aug; 113(8):1333-9.
-
Webster GF. Safety and efficacy of Tretin-X compared with Retin-A in patients with mild-to-severe acne vulgaris. Skinmed. 2006 May-Jun; 5(3):114-8.